PTEN and cancer: However, genomic alterations in androgen signaling, the rearrangement of ETS transcription factors, especially the fusion of TMPRSS2-ERG [37], as well as the deletion of PTEN [38] are known to be highly recurrent in primary cancers [39], early-onset cancers [40] and castration-resistant prostate cancers [41].